Buchumschlag

Antibody-drug conjugates: what drives their progress?

Antibody-drug conjugates (ADCs) are on the brink of widespread use for the targeted treatment of cancer. ADCs manage the toxicity of drugs with unacceptable narrow therapeutic windows by guiding highly toxic compounds to the target cells, thereby sparing healthy cells. In this review, we describe ap...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Pander, Giulia (VerfasserIn) , Uhl, Philipp (VerfasserIn) , Kühl, Nikos (VerfasserIn) , Haberkorn, Uwe (VerfasserIn) , Anderl, Jan (VerfasserIn) , Mier, Walter (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: [October 2022]
In: Drug discovery today
Year: 2022, Jahrgang: 27, Heft: 10, Pages: 1-10
ISSN:1878-5832
DOI:10.1016/j.drudis.2022.06.011
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.drudis.2022.06.011
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S1359644622002811
Volltext
Verfasserangaben:Giulia Pander, Philipp Uhl, Nikos Kühl, Uwe Haberkorn, Jan Anderl, Walter Mier

MARC

LEADER 00000caa a2200000 c 4500
001 1828153508
003 DE-627
005 20230426192853.0
007 cr uuu---uuuuu
008 221220s2022 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.drudis.2022.06.011  |2 doi 
035 |a (DE-627)1828153508 
035 |a (DE-599)KXP1828153508 
035 |a (OCoLC)1361669651 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Pander, Giulia  |e VerfasserIn  |0 (DE-588)1276202776  |0 (DE-627)1828154032  |4 aut 
245 1 0 |a Antibody-drug conjugates  |b what drives their progress?  |c Giulia Pander, Philipp Uhl, Nikos Kühl, Uwe Haberkorn, Jan Anderl, Walter Mier 
264 1 |c [October 2022] 
300 |b Illustrationen 
300 |a 10 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 20.12.2022 
520 |a Antibody-drug conjugates (ADCs) are on the brink of widespread use for the targeted treatment of cancer. ADCs manage the toxicity of drugs with unacceptable narrow therapeutic windows by guiding highly toxic compounds to the target cells, thereby sparing healthy cells. In this review, we describe approved ADCs and discuss their modes of action, together with medicinal chemical aspects, to evaluate the potential for improvement and to combat tumor-acquired resistance. A recent research focus has centered on the stimulation of immune responses to induce immunogenic cell death and the influence on the tumor microenvironment to enhance bystander effects. 
650 4 |a Antibody-drug conjugates 
650 4 |a Chemotherapy 
650 4 |a Drug delivery 
650 4 |a Drug resistance 
650 4 |a Monoclonal antibodies 
650 4 |a Toxins 
650 4 |a Tumor targeting 
700 1 |a Uhl, Philipp  |e VerfasserIn  |0 (DE-588)1112349391  |0 (DE-627)866420797  |0 (DE-576)476575230  |4 aut 
700 1 |a Kühl, Nikos  |d 1991-  |e VerfasserIn  |0 (DE-588)1218234296  |0 (DE-627)1733653430  |4 aut 
700 1 |a Haberkorn, Uwe  |d 1959-  |e VerfasserIn  |0 (DE-588)1022913905  |0 (DE-627)717331245  |0 (DE-576)366166352  |4 aut 
700 1 |a Anderl, Jan  |e VerfasserIn  |0 (DE-588)1156539722  |0 (DE-627)1019337192  |0 (DE-576)502233664  |4 aut 
700 1 |a Mier, Walter  |d 1966-  |e VerfasserIn  |0 (DE-588)12029026X  |0 (DE-627)69653567X  |0 (DE-576)292141599  |4 aut 
773 0 8 |i Enthalten in  |t Drug discovery today  |d Amsterdam [u.a.] : Elsevier Science, 1996  |g 27(2022), 10 vom: Okt., Artikel-ID 103311, Seite 1-10  |h Online-Ressource  |w (DE-627)306658348  |w (DE-600)1500337-1  |w (DE-576)259270970  |x 1878-5832  |7 nnas  |a Antibody-drug conjugates what drives their progress? 
773 1 8 |g volume:27  |g year:2022  |g number:10  |g month:10  |g elocationid:103311  |g pages:1-10  |g extent:10  |a Antibody-drug conjugates what drives their progress? 
856 4 0 |u https://doi.org/10.1016/j.drudis.2022.06.011  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://www.sciencedirect.com/science/article/pii/S1359644622002811  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20221220 
993 |a Article 
994 |a 2022 
998 |g 12029026X  |a Mier, Walter  |m 12029026X:Mier, Walter  |d 910000  |d 911400  |d 140000  |e 910000PM12029026X  |e 911400PM12029026X  |e 140000PM12029026X  |k 0/910000/  |k 1/910000/911400/  |k 0/140000/  |p 5 
998 |g 1022913905  |a Haberkorn, Uwe  |m 1022913905:Haberkorn, Uwe  |d 910000  |d 911400  |e 910000PH1022913905  |e 911400PH1022913905  |k 0/910000/  |k 1/910000/911400/  |p 4 
998 |g 1218234296  |a Kühl, Nikos  |m 1218234296:Kühl, Nikos  |p 3 
998 |g 1112349391  |a Uhl, Philipp  |m 1112349391:Uhl, Philipp  |d 160000  |d 160100  |e 160000PU1112349391  |e 160100PU1112349391  |k 0/160000/  |k 1/160000/160100/  |p 2 
998 |g 1276202776  |a Pander, Giulia  |m 1276202776:Pander, Giulia  |p 1  |x j 
999 |a KXP-PPN1828153508  |e 4236023598 
BIB |a Y 
SER |a journal 
JSO |a {"physDesc":[{"extent":"10 S.","noteIll":"Illustrationen"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"id":{"doi":["10.1016/j.drudis.2022.06.011"],"eki":["1828153508"]},"relHost":[{"recId":"306658348","disp":"Antibody-drug conjugates what drives their progress?Drug discovery today","language":["eng"],"pubHistory":["1.1996 -"],"type":{"media":"Online-Ressource","bibl":"periodical"},"origin":[{"dateIssuedKey":"1996","publisherPlace":"Amsterdam [u.a.]","publisher":"Elsevier Science","dateIssuedDisp":"1996-"}],"title":[{"title":"Drug discovery today","title_sort":"Drug discovery today"}],"physDesc":[{"extent":"Online-Ressource"}],"id":{"issn":["1878-5832"],"zdb":["1500337-1"],"eki":["306658348"]},"part":{"issue":"10","extent":"10","pages":"1-10","year":"2022","text":"27(2022), 10 vom: Okt., Artikel-ID 103311, Seite 1-10","volume":"27"},"note":["Gesehen am 08.02.2021"]}],"note":["Gesehen am 20.12.2022"],"person":[{"role":"aut","display":"Pander, Giulia","given":"Giulia","family":"Pander"},{"role":"aut","family":"Uhl","display":"Uhl, Philipp","given":"Philipp"},{"family":"Kühl","display":"Kühl, Nikos","given":"Nikos","role":"aut"},{"display":"Haberkorn, Uwe","given":"Uwe","family":"Haberkorn","role":"aut"},{"role":"aut","given":"Jan","display":"Anderl, Jan","family":"Anderl"},{"role":"aut","display":"Mier, Walter","given":"Walter","family":"Mier"}],"recId":"1828153508","origin":[{"dateIssuedKey":"2022","dateIssuedDisp":"[October 2022]"}],"name":{"displayForm":["Giulia Pander, Philipp Uhl, Nikos Kühl, Uwe Haberkorn, Jan Anderl, Walter Mier"]},"language":["eng"],"title":[{"title":"Antibody-drug conjugates","title_sort":"Antibody-drug conjugates","subtitle":"what drives their progress?"}]} 
SRT |a PANDERGIULANTIBODYDR2022 

Ähnliche Einträge